Johns Hopkins ABX Guide
Lefamulin
INDICATIONS
FDA
FDA
- Treatment of community-acquired pneumonia caused by susceptible organisms.
- Streptococcus pneumoniae, methicillin-susceptible Staphylococcus aureus, Haemophilus influenzae,Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- In vitro activity has been demonstrated against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium, multidrug-resistant Neisseria gonorrhoeae, and Mycoplasma genitalium.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 3, 2020
Citation
Bernice, Fidelia. "Lefamulin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540731/all/Lefamulin.
Bernice F. Lefamulin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540731/all/Lefamulin. Accessed November 21, 2024.
Bernice, F. (2020). Lefamulin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540731/all/Lefamulin
Bernice F. Lefamulin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2024 November 21]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540731/all/Lefamulin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Lefamulin
ID - 540731
A1 - Bernice,Fidelia,Pharm.D.
Y1 - 2020/07/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540731/all/Lefamulin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
